利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

13 条记录 (耗时 0.022 秒)

    Proceeding for the production of pharmaceutical preparations of high gastric acid binding capacity, of retarded effect and of increased bioavailability
    4.
    发明授权
    Proceeding for the production of pharmaceutical preparations of high gastric acid binding capacity, of retarded effect and of increased bioavailability 失效
    开展生产具有高胃酸结合能力，延迟作用和提高生物利用度的药物制剂

    公开(公告)号：US4921707A

    公开(公告)日：1990-05-01

    申请号：US165102

    申请日：1988-03-28

    申请人： Istvan Racz ,  Janos Plachy ,  Peter Szentmiklosi

    发明人： Istvan Racz ,  Janos Plachy ,  Peter Szentmiklosi

    IPC分类号： A61K9/00 ,  A61K9/16 ,  A61K9/20 ,  A61K9/22 ,  A61K33/08

    CPC分类号： A61K9/0095 ,  A61K33/08 ,  A61K9/1635 ,  A61K9/1652 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/2072 ,  A61K9/2077

    摘要： The invention relates to the production of a new pharmaceutical preparation of high acid-binding capacity, of delayed effect, of increased bioavailability for neutralization of gastric acid and eventually to other pharmaceutical preparations acting in the gastrointestinal tract, first of all of laxative effect by mixing 100 parts by mass of a powdered basic magnesium compound or the powdered mixture of basic magnesium compounds and basic aluminum compounds with 2-2500 parts of a dry or water-swollen organic acid of polymeric character and therapeutically acceptable, e.g. cellulose-glycolic acid, starch-glycolic acid or polymer acrylic and/or methacrylic acid, letting this powdered mixture to stand for 1-24 hours at the temperature of 20.degree.-80.degree. C. after addition of 50-500 parts by mass of water and forming tablets or other pharmaceutical preparations, optionally after addition of 5-60 parts by mass of smoothing agents and/or other pharmaceutical excipients, or transforming the mixture containing the basic active ingredients and the polymeric organic acid in liquid suspension by adding water and optionally excipients.

    摘要翻译： PCT No.PCT / HU87 / 00026 Sec。 371日期：1988年3月28日 102（e）1988年3月28日PCT申请1987年6月24日PCT公布。 第WO88 / 00051号公报 日期：1988年1月14日。本发明涉及生产具有较高的酸结合能力，延迟作用，增加生物利用度的中和酸性药物，最终涉及作用于胃肠道的其他药物制剂的新型药物制剂 通过将100质量份的粉状碱性镁化合物或碱性镁化合物和碱性铝化合物的粉末混合物与2-2500份具有聚合特性的干燥或水溶胀的有机酸和治疗上可接受的混合物混合， 例如 纤维素 - 乙醇酸，淀粉 - 乙醇酸或聚合物丙烯酸和/或甲基丙烯酸，使该粉末混合物在20〜80℃的温度下静置1-24小时，加入50-500质量份 水和成型片剂或其它药物制剂，任选地在加入5-60质量份平滑剂和/或其它药物赋形剂之后，或通过加入水和/或将其中含有碱性活性成分和聚合有机酸的混合物转化为液体悬浮液 任选的赋形剂。

    Process for the production of stable liquid form of beta-blocker-containing medicaments with controlled release of the active constituent for oral administration
    5.
    发明授权
    Process for the production of stable liquid form of beta-blocker-containing medicaments with controlled release of the active constituent for oral administration 失效
    用于生产具有控制释放口服给药活性成分的含β-阻滞剂的药物的稳定液体形式的方法

    公开(公告)号：US5484776A

    公开(公告)日：1996-01-16

    申请号：US135992

    申请日：1993-10-14

    申请人： Istvan Racz ,  Sylvia Marton

    发明人： Istvan Racz ,  Sylvia Marton

    IPC分类号： A61K9/00 ,  A61K31/135 ,  A61K31/165 ,  A61K31/40 ,  A61K47/36 ,  A61K9/08 ,  A61K47/26

    CPC分类号： A61K9/0095 ,  A61K31/135 ,  A61K31/165 ,  A61K31/40 ,  A61K47/36 ,  Y10S514/965

    摘要： This invention relates to a process for the production of optimally stable orally administrable solution forms of medicaments containing high-molecular polysaccharides, with controlled release of drugs having beta-blocking action, this process consisting of the reacting of 1 to 20 parts (w/w) of beta-blocking agent (oxprenolol, pindolol, sotalol, metoprolol, alprenolol, acebutolol, atenolol, bopindolol, practolol, nadolol or propranolol) in 100 parts of an aqueous solution with 0.001 to 10.0 parts of a polysaccharide polymer, advantageously with Xanthan Gum having beta-1,4-glucan chain, or dextran, or amylodextrin, or carboxymethylamylum. The reaction is allowed to take place in the course of 20 minutes at a pH adjusted no 2.0-4.5, with vigorous stirring at 80.degree. C. temperature. Following the usual method of the pharmaceutical practice, the system is then formulated by the addition of water to obtain a solution suitable for oral administration.

    摘要翻译： 本发明涉及一种生产含有高分子多糖的药物的最佳稳定的口服给药溶液形式的方法，具有β-阻断作用的药物的控制释放，该方法由1至20份（w / w） ）在100份具有0.001至10.0份多糖聚合物的水溶液中，有利地与黄原胶一起使用β-阻断剂（oxprenolol，吲哚洛尔，索他洛尔，美托洛尔，阿普洛尔，acebutolol，阿替洛尔，bopindolol，实心洛芬，纳多洛尔或普萘洛尔） 具有β-1,4-葡聚糖链，或葡聚糖，或淀粉糊精，或羧甲基淀粉。 反应在20分钟内进行，调节pH为2.0-4.5，在80℃温度下剧烈搅拌。 按照药物实践的常规方法，然后通过加入水来配制该体系以获得适合于口服给药的溶液。

    Stabilized plant protecting carbofuran suspensions
    7.
    发明授权
    Stabilized plant protecting carbofuran suspensions 失效
    稳定植物保护呋喃丹悬浮液

    公开(公告)号：US4734432A

    公开(公告)日：1988-03-29

    申请号：US831467

    申请日：1986-02-19

    申请人： Andras Szego ,  Viktoria Peterdi ,  Ferenc Kovats ,  Jozsef Sos ,  Istvan Racz ,  Sandor ngyan ,  Katalin Marmarosi nee Kellner

    发明人： Andras Szego ,  Viktoria Peterdi ,  Ferenc Kovats ,  Jozsef Sos ,  Istvan Racz ,  Sandor ngyan ,  Katalin Marmarosi nee Kellner

    IPC分类号： A01N47/18 ,  A01N25/04 ,  A01N47/22 ,  A01N43/08

    CPC分类号： A01N25/04

    摘要： The present invention relates to a stabilized plant protecting agent suspension which can be characterized by containing 10 to 60% by weight of one or more active ingredients, 30 to 5% by weight of oily layer, 0 to 10% by weight of emulsifier, 10 to 20% by weight of conventionally used excipient and water needed to 100% by weight while by increasing solid concentration oil concentration decreases. The invention also provides a process for the preparation of a stabilized plant protecting agent suspension by adding oil and optionally an emulsifier and/or water containing layer to a suspension of a suitable particle size of the active ingredient and water soluble excipients, such as surfactants, optionally emulsifiers, dispersing agents, viscosity modifying agents, protective colloids and mixing together the suspension layer and the layer containing the oil with a stirrer of great shearing force and optionally adding to the obtained stabilized suspension further excipients, e.g. viscosity modifying agents, anti-foaming agent, protective colloid and dispersing agent.

    摘要翻译： 本发明涉及稳定的植物保护剂悬浮液，其特征在于含有10至60重量％的一种或多种活性成分，30至5重量％的油层，0至10重量％的乳化剂，10 至20重量％的常规使用的赋形剂和水需要100重量％，同时通过提高固体浓度油浓度降低。 本发明还提供了一种制备稳定的植物保护剂悬浮液的方法，其通过将油和任选的乳化剂和/或含水层加入到适合的粒度的活性成分和水溶性赋形剂如表面活性剂的悬浮液中， 任选的乳化剂，分散剂，粘度调节剂，保护胶体，并将悬浮液层和含有油的层与具有大剪切力的搅拌器混合在一起，并任选地将所得稳定悬浮液中的其它赋形剂 粘度调节剂，消泡剂，保护胶体和分散剂。

    Stabilized plant protecting agent suspension
    8.
    发明授权
    Stabilized plant protecting agent suspension 失效
    稳定植物保护剂悬浮液

    公开(公告)号：US4826863A

    公开(公告)日：1989-05-02

    申请号：US84986

    申请日：1987-08-12

    申请人： Andras Szego ,  Viktoria Peterdi ,  Ferenc Kovats ,  Jozsef Sos ,  Istvan Racz ,  Sandor ngyan ,  Katalin Marmarosi nee Kellner

    发明人： Andras Szego ,  Viktoria Peterdi ,  Ferenc Kovats ,  Jozsef Sos ,  Istvan Racz ,  Sandor ngyan ,  Katalin Marmarosi nee Kellner

    IPC分类号： A01N47/18 ,  A01N25/04 ,  A01N47/22 ,  A01N43/52

    CPC分类号： A01N25/04

    摘要： The present invention relates to a stabilized plant protecting agent suspension which can be characterized by containing 10 to 60% by weight of one or more active ingredients, 30 to 5% by weight of oily layer, 0 to 10% by weight of emulsifyer, 10 to 20% by weight of conventionally used excipient and water needed to 100% by weight while by increasing solid concentration oil concentration decreases.The invention also provides a process for the preparation of a stabilized plant protecting agent suspension by adding oil and optionally an emulsifyer and/or water containing layer to a suspension of a suitable particle size of the active ingredient and water soluble excipients, such as surfactants, optionally emulsifiers, dispersing agents, viscosity modifying agents, protective colloids and mixing together the suspension layer and the layer containing the oil with a stirrer of great shearing force and optionally adding to the obtained stabilized suspension further excipients, e.g. viscosity modifying agents, anti-foaming agent, protective colloid and dispersing agent.

    摘要翻译： 本发明涉及一种稳定的植物保护剂悬浮液，其特征在于含有10至60重量％的一种或多种活性成分，30至5重量％的油层，0至10重量％的乳化剂，10 至20重量％的常规使用的赋形剂和水需要100重量％，同时通过提高固体浓度油浓度降低。 本发明还提供了一种制备稳定的植物保护剂悬浮液的方法，其通过将油和任选的乳化剂和/或含水层添加到适合粒度的活性成分和水溶性赋形剂如表面活性剂的悬浮液中， 任选的乳化剂，分散剂，粘度调节剂，保护胶体，并将悬浮液层和含有油的层与具有大剪切力的搅拌器混合在一起，并任选地将所得稳定悬浮液中的其它赋形剂 粘度调节剂，消泡剂，保护胶体和分散剂。

    Solid oral pharmaceutical product with increased efficacy and predetermined steady state of solubility
    9.
    发明授权
    Solid oral pharmaceutical product with increased efficacy and predetermined steady state of solubility 失效
    固体口服药物具有增加的疗效和预定的稳定状态的溶解度

    公开(公告)号：US4199560A

    公开(公告)日：1980-04-22

    申请号：US952932

    申请日：1978-10-19

    申请人： Laszlo Gyarmati ,  Istvan Racz ,  Peter Szentmiklosi ,  Janos Plachy

    发明人： Laszlo Gyarmati ,  Istvan Racz ,  Peter Szentmiklosi ,  Janos Plachy

    IPC分类号： A61K9/16 ,  A61K9/20 ,  A61K9/22 ,  A61K9/48 ,  A61K9/26 ,  A61K9/54 ,  A61K33/06

    CPC分类号： A61K9/1652 ,  A61K9/1617 ,  A61K9/2077 ,  A61K9/4841

    摘要： The present invention relates to a solid oral pharmaceutical preparation with protracted release of the active ingredient consisting of discrete solid granules containing the active ingredient soluble in the stomach and auxiliary agents and of an equally solid external phase surrounding the said granules, whereby the granules forming the internal phase consist of granules prepared from a powder mixture which contains as active ingredient, or in addition to it a non-toxic metal compound, being capable of binding an acid, and being insoluble or but slightly soluble in neutral aqueous medium--particularly bismuth, aluminium or magnesium compound--and auxiliary materials prepared with an aqueous emulsion containing a hydrophobic component and hydrophylic emulsifiers, and the external phase contains a solid, dry, amphoteric gel forming substance in an amount of 1-50 percent w/w related to the total weight of the preparation in admixture with auxiliary agents.The preparation is produced by the wetting of the powder mixture containing the basic metal compound, auxiliary material and in given case additional active ingredient with the aqueous emulsion of the hydrophobic component prepared by applying the hydrophylic emulsifiers then by granulation and admixing the dried granules with the amphoteric gel forming substance, and pressing it into tablets, or filling into capsules.

    摘要翻译： 本发明涉及具有长时间释放的活性成分的固体口服药物制剂，其由分散的固体颗粒组成，所述固体颗粒含有可溶于胃的活性成分和辅助剂以及围绕所述颗粒的同样固体的外部相，其中颗粒形成 内相包含由粉末混合物制成的颗粒，所述粉末混合物含有作为活性成分的粉末混合物，或除此之外，还含有无毒金属化合物，其能够结合酸，并且在中性水性介质（特别是铋）中不溶或略微溶解， 铝或镁化合物以及用含有疏水组分和亲水乳化剂的水性乳液制备的辅助材料，并且外相含有与总量相关的1-50％w / w的固体，干燥，两性凝胶形成物质 制剂的重量与助剂混合。 该制备是通过润湿包含碱性金属化合物，辅助材料的粉末混合物，并且在给定情况下，通过施用亲水性乳化剂制备疏水组分的水性乳液，然后通过造粒和将干燥颗粒与 两性凝胶形成物质，并将其压制成片剂或填充到胶囊中。

    Pharmaceutical preparations of high gastric acid binding capacity, delayed effect and of increased bioavailability
    10.
    发明授权
    Pharmaceutical preparations of high gastric acid binding capacity, delayed effect and of increased bioavailability 失效
    高酸性结合能力的药物制备，延迟效应和增加的生物利用度

    公开(公告)号：US5087447A

    公开(公告)日：1992-02-11

    申请号：US420280

    申请日：1989-10-12

    申请人： Istvan Racz ,  Janos Plachy ,  Peter Szentmiklost

    发明人： Istvan Racz ,  Janos Plachy ,  Peter Szentmiklost

    IPC分类号： A61K9/00 ,  A61K9/16 ,  A61K9/20 ,  A61K9/22 ,  A61K33/08

    CPC分类号： A61K9/0095 ,  A61K33/08 ,  A61K9/1635 ,  A61K9/1652 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/2072 ,  A61K9/2077

    摘要： The invention relates to a new pharmaceutical preparation of high acid-binding capacity, of delayed effect, of increased bioavailability for neutralization of gastric acid and optionally to other pharmaceutical preparations acting in the gastrointestinal tract, first of all of laxative effect by mixing 100 parts by mass of a powdered basic magnesium compound or the powdered mixture of basic magnesium compounds and basic aluminium compounds with 2-2500 parts of a dry or swollen organic acid of polymeric character and therapeutically acceptable, e.g. cellulose-glycolic acid, starch-glycolic acid or polymer acrylic and/or methacrylic acid, letting this powdered mixture to stand for 1-24 hours at the temperature of 20.degree.-80.degree. C. after addition of 50-500 parts by mass of water and forming tablets or other pharmaceutical preparations, optionally after addition of 5-60 parts by mass of smoothing agents and/or other pharmaceutical excipients, or transforming the mixture containing the basic active ingredients and the polymeric organic acid in liquid suspension by adding water and optionally excipients.